Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Labetuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Labetuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Labetuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Labetuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Labetuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Labetuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Labetuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Labetuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Labetuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Labetuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Labetuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Labetuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Labetuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Labetuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Labetuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Labetuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Labetuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Labetuzumab. |
| Equol | Equol may increase the thrombogenic activities of Labetuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Labetuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Labetuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Labetuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Labetuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Labetuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Labetuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Labetuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Labetuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Labetuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Labetuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Labetuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Labetuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Labetuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Labetuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Labetuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Labetuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Labetuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Labetuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Labetuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Labetuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Labetuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Labetuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Labetuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Labetuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Labetuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Labetuzumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Canakinumab. |